FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899590947> ?p ?o ?g. }

• W2899590947 endingPage "645" @default.
• W2899590947 startingPage "636" @default.
• W2899590947 abstract "Ventricular tachycardia (VT) and ventricular fibrillation (VF) remain a challenging problem in patients with implantable cardioverter-defibrillators (ICDs). This study aimed to determine whether ranolazine administration decreases the likelihood of VT, VF, or death in patients with an ICD. This was double-blind, placebo-controlled clinical trial in which high-risk ICD patients with ischemic or nonischemic cardiomyopathy were randomized to 1,000 mg ranolazine twice a day or placebo. The primary endpoint was VT or VF requiring appropriate ICD therapy or death, whichever occurred first. Pre-specified secondary endpoints included ICD shock for VT, VF, or death and recurrent VT or VF requiring ICD therapy. Among 1,012 ICD patients (510 randomized to ranolazine and 502 to placebo) the mean age was 64 ± 10 years and 18% were women. During 28 ± 16 months of follow-up there were 372 (37%) patients with primary endpoint, 270 (27%) patients with VT or VF, and 148 (15%) deaths. The blinded study drug was discontinued in 199 (39.6%) patients receiving placebo and in 253 (49.6%) patients receiving ranolazine (p = 0.001). The hazard ratio for ranolazine versus placebo was 0.84 (95% confidence interval: 0.67 to 1.05; p = 0.117) for VT, VF, or death. In a pre-specified secondary analysis, patients randomized to ranolazine had a marginally significant lower risk of ICD therapies for recurrent VT or VF (hazard ratio: 0.70; 95% confidence interval: 0.51 to 0.96; p = 0.028). There were no other significant treatment effects in other pre-specified secondary analyses, which included individual components of the primary endpoint, inappropriate shocks, cardiac hospitalizations, and quality of life. In high-risk ICD patients, treatment with ranolazine did not significantly reduce the incidence of the first VT or VF, or death. However, the study was underpowered to detect a difference in the primary endpoint. In prespecified secondary endpoint analyses, ranolazine administration was associated with a significant reduction in recurrent VT or VF requiring ICD therapy without evidence for increased mortality. (Ranolazine Implantable Cardioverter-Defibrillator Trial [RAID]; NCT01215253)" @default.
• W2899590947 created "2018-11-16" @default.
• W2899590947 creator A5000572985 @default.
• W2899590947 creator A5000997969 @default.
• W2899590947 creator A5001088376 @default.
• W2899590947 creator A5001298251 @default.
• W2899590947 creator A5001501076 @default.
• W2899590947 creator A5001619846 @default.
• W2899590947 creator A5002121570 @default.
• W2899590947 creator A5002856525 @default.
• W2899590947 creator A5003099415 @default.
• W2899590947 creator A5003195419 @default.
• W2899590947 creator A5004707994 @default.
• W2899590947 creator A5004712840 @default.
• W2899590947 creator A5004778657 @default.
• W2899590947 creator A5004913924 @default.
• W2899590947 creator A5005216429 @default.
• W2899590947 creator A5006422878 @default.
• W2899590947 creator A5006437491 @default.
• W2899590947 creator A5006572081 @default.
• W2899590947 creator A5007202277 @default.
• W2899590947 creator A5008188762 @default.
• W2899590947 creator A5008613276 @default.
• W2899590947 creator A5008829494 @default.
• W2899590947 creator A5013872909 @default.
• W2899590947 creator A5016050910 @default.
• W2899590947 creator A5016673974 @default.
• W2899590947 creator A5018413369 @default.
• W2899590947 creator A5018802200 @default.
• W2899590947 creator A5020171172 @default.
• W2899590947 creator A5020531014 @default.
• W2899590947 creator A5021262405 @default.
• W2899590947 creator A5021594296 @default.
• W2899590947 creator A5022185581 @default.
• W2899590947 creator A5022198058 @default.
• W2899590947 creator A5023287512 @default.
• W2899590947 creator A5023346746 @default.
• W2899590947 creator A5024433352 @default.
• W2899590947 creator A5025016157 @default.
• W2899590947 creator A5025657827 @default.
• W2899590947 creator A5026353569 @default.
• W2899590947 creator A5026475907 @default.
• W2899590947 creator A5027822736 @default.
• W2899590947 creator A5027926413 @default.
• W2899590947 creator A5029137282 @default.
• W2899590947 creator A5029885472 @default.
• W2899590947 creator A5030159733 @default.
• W2899590947 creator A5030375757 @default.
• W2899590947 creator A5030644838 @default.
• W2899590947 creator A5030796618 @default.
• W2899590947 creator A5030817967 @default.
• W2899590947 creator A5031045486 @default.
• W2899590947 creator A5031646811 @default.
• W2899590947 creator A5032171685 @default.
• W2899590947 creator A5033720138 @default.
• W2899590947 creator A5034901265 @default.
• W2899590947 creator A5035096867 @default.
• W2899590947 creator A5036243160 @default.
• W2899590947 creator A5037259157 @default.
• W2899590947 creator A5040804435 @default.
• W2899590947 creator A5040984504 @default.
• W2899590947 creator A5041037196 @default.
• W2899590947 creator A5041049848 @default.
• W2899590947 creator A5042352003 @default.
• W2899590947 creator A5042449018 @default.
• W2899590947 creator A5042495676 @default.
• W2899590947 creator A5043416120 @default.
• W2899590947 creator A5045073477 @default.
• W2899590947 creator A5045109483 @default.
• W2899590947 creator A5047355787 @default.
• W2899590947 creator A5047883987 @default.
• W2899590947 creator A5048488230 @default.
• W2899590947 creator A5049056497 @default.
• W2899590947 creator A5049632213 @default.
• W2899590947 creator A5049961500 @default.
• W2899590947 creator A5050117038 @default.
• W2899590947 creator A5051064863 @default.
• W2899590947 creator A5051372918 @default.
• W2899590947 creator A5052113776 @default.
• W2899590947 creator A5052429527 @default.
• W2899590947 creator A5054707028 @default.
• W2899590947 creator A5056066828 @default.
• W2899590947 creator A5056349105 @default.
• W2899590947 creator A5056501310 @default.
• W2899590947 creator A5057011828 @default.
• W2899590947 creator A5057692889 @default.
• W2899590947 creator A5058588504 @default.
• W2899590947 creator A5058703866 @default.
• W2899590947 creator A5058912156 @default.
• W2899590947 creator A5060625026 @default.
• W2899590947 creator A5060934334 @default.
• W2899590947 creator A5061365300 @default.
• W2899590947 creator A5061668237 @default.
• W2899590947 creator A5062528311 @default.
• W2899590947 creator A5063751182 @default.
• W2899590947 creator A5063831619 @default.
• W2899590947 creator A5064289374 @default.
• W2899590947 creator A5064750864 @default.

• next